Inhibition of miR-33a/b in non-human primates raises plasma HDL and reduces VLDL triglycerides

Systemic delivery of anti-miR-33 in African green monkeys induced a sustained 50% increase in plasma HDL cholesterol over 12 weeks, with corresponding increases in HDL-associated apolipoproteins AI an

Effect: improvement; 50% increase in HDL cholesterol at 8 weeks, sustained through 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study